-- Robert Preidt
TUESDAY, Oct. 26 (HealthDay News) -- A new bivalent oral vaccine
that targets two deadly strains of polio -- types 1 and 3 --
triggers a stronger immune response than the existing trivalent
vaccine and an immune response that's similar to monovalent
vaccines, a new study shows.
Use of trivalent and monovalent vaccines has reduced the number
of countries where polio is endemic from more than 125 in 1988 to
just four today. Transmission of polio virus types 1 and 3 persists
in parts of Afghanistan, Pakistan, India and Nigeria.
The bivalent oral vaccine is already widely used in efforts to
halt transmission of polio virus types 1 and 3, but this study set
out to examine whether it triggers as much immunity as the other
Between August and December 2008, researchers gave 830 newborns
in India either the monovalent, bivalent or trivalent vaccines in
two doses, including one at birth and one 30 days later. Antibody
levels were measured in blood samples before vaccination and after
the first and second doses of the vaccines.
Overall, the immune response induced by the bivalent vaccine was
significantly higher than the trivalent vaccine and similar to the
monovalent vaccine, the investigators found.
The study was released online Oct. 25 in advance of publication
in an upcoming print issue of
"The major advantages of the bivalent vaccine ... is that it will enhance individual and population immunity simultaneously for both poliovirus types 1 and 3, without any serious loss in immunogenicity compared with the [monovalent vaccines]," the researchers said in a news release from the publisher.
The American Academy of Family Physicians has more about
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.